traded as omx wtx industry pharmaceutical industry founded 2012 headquarters stockholm sweden products decuprate website www.wilsontherapeutics.com wilson therapeutics is a biopharmaceutical company based in stockholm sweden that develops novel therapies for rare diseases . the company is listed in the mid cap segment on nasdaq stockholm with the stock ticker wtx . wilson therapeutics lead product decuprate is the proprietary bis choline salt of tetrathiomolybdate . decuprate is initially being developed as a novel treatment for wilson s disease a rare genetic disease that affects approximately 1 in 30 000 causing copper overload in the liver brain and other tissues and resulting in organ damage and dysfunction . 1 decuprate has been granted orphan drug designation for the treatment of wilson s disease in both europe and the united states . 2 clinical trials edit as of 2016 tetrathiomolybdate had been tested in over 500 patients for up to seven years primarily in oncology 3 4 5 6 7 8 9 10 11 12 and wilson s disease 13 14 15 16 as well as some other clinical pathologies . 17 18 history edit wilson therapeutics was founded in 2012 by healthcap one of the leading european life science venture capital funds . 19 in 2014 wilson therapeutics closed a 40 million series b financing co led by new investors abingworth llp mvm life science partners llp and neomed management as . healthcap also participated in the round . 20 21 on april 29 2016 wilson therapeutics announced its initial public offering on nasdaq stockholm and had its first day of trading on may 12 2016 . 22 23 references edit ala a walker ap ashkan k dooley js schilsky ml . 2007 . wilson s disease . lancet 369 397 408 . 1 u.s. food and drug administration orphan drug designations and approvals berenson jr boccia rv bashey a levine am koc on callahan ja mazar ap reich sd 2006 . phase i study of the cu zn superoxide dismutase sod1 inhibitor atn 224 bis choline tetrathiomolybdate in patients with advanced hematologic malignancies . presentation at the amer soc hematol 2006 annual meeting . blood 108 abstract 2593 . brewer gj dick rd grover dk leclaire v tseng m wicha m pienta k redman bg jahan t sondak vk strawderman m lecarpentier g merajver sd 2000 . treatment of metastatic cancer with tetrathiomolybdate an anticopper antiangiogenic agent phase i study . clin cancer res 6 1 10 . gartner em griffith ka pan q brewer gj henja gf merajver sd zalupski mm 2009 . a pilot trial of the anti angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan 5 flurouracil and leucovorin for metastatic colorectal cancer . invest new drugs 27 159 165 . henry nl dunn r merjaver s pan q pienta kj brewer g smith dc 2006 . phase ii trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer . oncology 71 168 175 . jain s cohen j ward mm kornhauser n chuang e cigler t moore a donovan d lam c cobham mv schneider s hurtado rua sm benkert s mathijsen greenwood c zelkowitz r warren jd lane me mittal v rafii s vahdat lt 2013 . tetrathiomolybdate associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse . annals of oncology . lin j zahurak m beer tm ryan cj wilding g mathew p morris m callahan ja gordon g reich sd carducci ma antonarakis es 2011 . a non comparative randomized phase ii study of 2 doses of atn 224 a copper zinc superoxide dismutase inhibitor in patients with biochemically recurrent hormone naive prostate cancer . urologic oncology . 31 5 581 8 . lowndes sa adams a timms a fisher n smythe j watt sm joel s donate f hayward c reich s middleton m mazar a harris al 2008 . phase i study of copper binding agent atn 224 in patients with advanced solid tumors . clin cancer res 14 7526 7534 . pass hi brewer gj dick r carbone m merajver s 2008 . a phase ii trial of tetrathiomolybdate after surgery for malignant mesothelioma final results . ann thorac surg 86 383 389 ; discussion 390 . redman bg esper p pan q dunn rl hussain hk chenevert t brewer gj merajver sd 2003 . phase ii trial of tetrathiomolybdate in patients with advanced kidney cancer . clin cancer res 9 1666 1672 . schneider bj lee js hayman ja chang ac orringer mb pickens a pan cc merajver sd urba sg 2012 . pre operative chemoradiation followed by post operative adjuvant therapy with tetrathiomolybdate a novel copper chelator for patients with resectable esophageal cancer . invest new drugs . roberts ea schilsky l 2008 . diagnosis and treatment of wilson disease an update . aasdl clinical practice guidelines in wilson disease . hepatology 47 6 2089 2111 . brewer gj askari f dick rb sitterly j fink jk carlson m kluin kj lorincz mt 2009 . treatment of wilson s disease with tetrathiomolybdate v. control of free copper by tetrathiomolybdate and a comparison with trientine . translational research 154 70 77 . brewer gj askari f lorincz mt carlson m schilsky m kluin kj hedera p moretti p fink jk tankanow r dick rb sitterly j 2006 . treatment of wilson disease with ammonium tetrathiomolybdate iv . comparison of tetrathiomolybdate and trientine in a double blind study of treatment of the neurologic presentation of wilson disease . arch neurol 63 521 527 . brewer gj hedera p kluin kj carlson m askari f dick rb sitterly j fink jk 2003 . treatment of wilson disease with ammonium tetrathiomolybdate iii . initial therapy in a total of 55 neurologically affected patients and follow up with zinc therapy . arch neurol 60 379 385 . askari f innis d dick rb hou g marrero j greenson j brewer gj 2010 . treatment of primary biliary cirrhosis with tetrathiomolybdate results of a double blind trial . translational research 155 123 130 . vine ak brewer gj 2002 . tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age related macular degeneration . trans am ophthalmol soc 100 73 76 ; discussion 76 77 . wilson therapeutics life science sweden . april 17 2014 . wilson therapeutics raises 40m series b to rid body of excess copper . private equity and venture capital dow jones . april 16 2014 . venture capitalists support new approach to pain . mednous opportunities in european medical innovation . 8 5 19 . may 2014 . 2 3 retrieved from https en.wikipedia.org w index.php title wilson therapeutics & oldid 741393539 categories pharmaceutical companiesrare diseasespharmaceutical industrymedical research organizationsgenetic diseases and disordersorphan drug companies navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 27 september 2016 at 06 31 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view